Nutrition and cardiometabolic health in cystic fibrosis: Emerging evidence and research gaps.

Antiviral defenses are diminished at birth in cystic fibrosis pig airways.

Real-world population pharmacokinetic modeling of elexacaftor, tezacaftor, and ivacaftor.

Forced vital capacity in pulmonary exacerbations of cystic fibrosis.

Timing and rate of reimbursement for cystic fibrosis modulator therapies in EU countries.

Improvement in functional exercise performance and quadriceps muscle strength after two years treatment with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: A prospective observational study.

Nutrition and cardiometabolic health in cystic fibrosis: Emerging evidence and research gaps.

Antiviral defenses are diminished at birth in cystic fibrosis pig airways.

Real-world population pharmacokinetic modeling of elexacaftor, tezacaftor, and ivacaftor.

Forced vital capacity in pulmonary exacerbations of cystic fibrosis.

Timing and rate of reimbursement for cystic fibrosis modulator therapies in EU countries.

Improvement in functional exercise performance and quadriceps muscle strength after two years treatment with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: A prospective observational study.